Current stock page

Catalysts

QURE Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

QUREuniQure N.V.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$23.81−$0.82 (−3.33%)

Latest quote

  • Momentum
    41
  • Value
    38
  • Quality
    42
  • Risk resilience
    31
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 1, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 39/100

Momentum 41/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 13.46%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 41/100AIQ Edge 2/10 Relative Laggard
Beat rate
63%
5 of 8 reported periods
Average surprise
-21.0%
Across covered historical reports
Latest result
+3.9%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$0.92-$0.88+3.9%$6.17M$5.2M
Jul 29, 2026—-$0.82-$1.22-48.4%$5.45M$5.84M
May 5, 2026—-$0.88-$0.85+3.4%$5.2M$3.56M
Mar 2, 2026—-$0.93-$0.56+39.8%$5.33M$5.57M
Nov 10, 2025—-$0.85-$1.38-62.4%$4.84M$3.7M
Jul 29, 2025—-$0.89-$0.69+22.5%$4.63M$5.26M
May 9, 2025—-$1.07-$0.82+23.4%$5.9M$1.57M
Feb 27, 2025—-$0.60-$1.50-150.0%$18.45M$5.22M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
2
Hold
12-month analyst target
$50.17
+110.70% versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
Low target
$28.00
+17.60% vs latest price
Average target
$50.17
+110.70% vs latest price
High target
$75.00
+214.99% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 1, 2027

Next known earnings or reporting date.

EPS estimate-$0.88

Current analyst expectation for the upcoming report.

Revenue estimate$6.66M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score41

Where event reaction would show up first.

AIQ score39/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13
Average target
$50.17
Target upside
110.70%
Target range
$28.00 - $75.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
3
Negative
0
seekingalpha.com · Nov 4, 2026

uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (NASDAQ:QURE)

uniQure's AMT-130 data likely remains strong enough to support accelerated approval, which isn't priced into the stock at the moment. Read more on QURE stock here.

markets.businessinsider.com · Nov 2, 2026

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

~ FDA sets PDUFA target action date of May 1, 2027 ~~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatmen...

gurufocus.com · Sep 29, 2026

uniQure N.V. Huntington's Disease Update Transcript

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NQURE.OQ - uniQure N.V.uniQure N.V. Huntington's Disease UpdateSep 29, 2026 / 12:30PM GMT =====

rttnews.com · Sep 29, 2026

UniQure Stock Falls 37% After Huntington's Disease Trial Update

Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington's disease.

insidermonkey.com · Sep 9, 2026

uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?

uniQure N.V. (NASDAQ:QURE) submitted a biologics license application, or BLA, to the U.S.

Open full news and sentiment

QURE Catalysts FAQ

What are the next catalysts for QURE stock?

QURE's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move QURE stock?

Upcoming events that could move QURE include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could QURE's next earnings report affect the stock?

QURE's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive QURE stock higher?

QURE could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt QURE stock?

QURE could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.